Filing Flows

Filing Flows › 8-K events › Allarity Therapeutics

Allarity Therapeutics: entry into a material definitive agreement

Form 8-K filed Nov 2, 2026 · items 1.01, 8.01

FDA decisionsAllarity Therapeutics Secures First Commercial Agreement Under New CLIA Laboratory Services Strategy, Establishing Potential Path to Additional Recurring Revenue

What the filing says

On October 28, 2026, Allarity Therapeutics, Inc. (the “Company”) entered into a Settlement and Release Agreement (the “Settlement Agreement”) with Novartis Pharma AG (“Novartis”) relating to an aggregate current liability of $4,900,000, plus interest, due to Novartis (the “Liability”). The Liability arose under a licen

ScaleThe filing names $4.9M: 49× Allarity Therapeutics' annual revenue ($100K, four times the latest quarter).

Read the filing on SEC EDGAR →

What usually followsAcross 23,525 8-Ks reporting Item 1.01 (material definitive agreement) in our universe, the stock's median move the next session was 0.0% (typical size ±1.4%, up 51% of the time); over the following 21 sessions, +1.0%. Item 8.01: +0.1% next session across 44,881. Every item ranked →

What this kind of filing means

Item 1.01 — Entry into a material definitive agreement. A material agreement is one the company considers important enough to disclose within four business days: a merger agreement, a large supply or customer contract, a credit agreement or a licence. The terms often move the company’s outlook more than a quarter’s results.

Allarity Therapeutics at a glance

Latest quarterQ1 2026
Revenue$25K
Operating marginn/m
IndustryPharmaceutical Preparations

Allarity Therapeutics, Q1 2026: revenue $25K. The chart follows the revenue to costs, profit and cash.

Allarity Therapeutics: every quarter, Q/Q and Y/Y, holders and guidance →

Allarity Therapeutics’s other material 8-Ks

Other recent fda decisions

Read automatically from SEC EDGAR (13F, Form 4, Form 144, Schedule 13D/G, 8-K, XBRL), House and Senate disclosures, FINRA and exchange data; errors are possible. Not investment advice.